Observational analysis found daratumumab improved progression-free survival in relapsed-refractory multiple myeloma, highlighting its potential as a second-line therapy.
Key Points
Daratumumab therapy achieved a 76.5% overall response rate in relapsed-refractory multiple myeloma patients.
The median progression-free survival was 20 months among patients receiving daratumumab as a second-line therapy.
This was a single-center observational case series involving retrospective chart reviews of multiple myeloma patients treated with daratumumab.
Findings suggest daratumumab may enable better outcomes for patients with relapsed-refractory multiple myeloma, although adverse effects were noted.